Despite HCM’s strong genetic basis, patients residing in lower-income or more socially deprived areas faced significantly ...
Everyday Health on MSN
Obstructive vs. Nonobstructive Hypertrophic Cardiomyopathy (HCM): What Your Diagnosis Means for Treatment and Lifestyle
Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...
GlobalData on MSN
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.
When it comes to heart health, heart attacks tend to get the spotlight. While 805,000 people die from heart attacks every ...
The Mirror US on MSN
Disease dubbed 'silent killer' as 85% of patients go undiagnosed
Hypertrophic cardiomyopathy is a genetic heart condition characterized by the thickening of the heart muscle, leading to ...
Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A small panel of ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...
Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback